Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft monograph: GHK-Cu — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-050/3
Series
Public comment period
Version
1.0
Published
27 Feb 2025
Last reviewed
27 Feb 2025
Next review
27 Feb 2026
Identifier
10.71829/cei.cp.50
Certainty
Not rated
Cycle
2025 Q1
Window
11 Jan 2025 – 08 Feb 2025
Status
Closed
Submissions
7

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-GHK-CU-MONOG/001Dr Valentin TollemacheWhat happens when the compound is stopped is not addressedAccepted
DRAFT-GHK-CU-MONOG/002Dr Ivo QuintanilhaThe certainty rating for the principal assessed outcome cannot be traced to the contributing trialsAccepted
DRAFT-GHK-CU-MONOG/003Eamon Sandringham-AduA superseded version should remain reachable from the version that replaced itNoted, no amendment
DRAFT-GHK-CU-MONOG/004Dr Perpetua Haverkamp-Diallo industryThe document should not describe uses outside the approved indicationNot accepted
DRAFT-GHK-CU-MONOG/005Dr Emiliana OllerenshawThe monograph should not describe how the compound is supplied outside a regulated routeNoted, no amendment
DRAFT-GHK-CU-MONOG/006Dr Constança Glendinning-UcheThe monograph should state what the compound costsNot accepted
DRAFT-GHK-CU-MONOG/007Dr Radoslava Palmgren-KofiNothing is said about impaired renal or hepatic clearanceAccepted
7 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted3The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part0Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment2The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted2The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. What happens when the compound is stopped is not addressed — arising from DRAFT-GHK-CU-MONOG/001. Discontinuation trajectory is now an assessed outcome in every monograph where a contributing trial measured it, and a recorded evidence gap in every monograph where none did, so that its absence is visible rather than silent.
  2. The certainty rating for the principal assessed outcome cannot be traced to the contributing trials — arising from DRAFT-GHK-CU-MONOG/002. Each assessed outcome now carries its downgrade domains in the summary-of-findings row, with a short statement of the judgement made in each, so that the rating can be checked domain by domain against the contributing trials.
  3. Nothing is said about impaired renal or hepatic clearance — arising from DRAFT-GHK-CU-MONOG/007. The pharmacokinetic table now carries renal and hepatic rows in every monograph, populated with the study where one exists and with an explicit statement of absence where none does.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.